What's in Universita di Verona's pipeline?

Universita di Verona has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Universita di Verona's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universita-di-verona.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universita di Verona — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universita di Verona pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
efalizumab plus acitretin	efalizumab plus acitretin	marketed	Monoclonal antibody + retinoid combination	CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR)	Dermatology/Immunology
Linear tapering	Linear tapering	marketed
Hyperbolic tapering	Hyperbolic tapering	marketed

Therapeutic area mix

Dermatology/Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universita di Verona:

Cite this brief

Drug Landscape (2026). Universita di Verona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universita-di-verona. Accessed 2026-05-17.